ArticleProstate international2025
Burden of prostate cancer in China during 1990-2021 and the projections through 2050.
Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predictors of false-positive results in men with Prostate Imaging-Reporting and Data System 4 lesions.Prostate international · 2026Article
- Hospitalization expenses for radical prostatectomy in a tertiary hospital in China: a quantile regression and CHAID decision tree analysis.BMC health services research · 2026Article
- Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review.Frontiers in health services · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To provide the most up-to-date data on the burden of prostate cancer (PC) in China and the projections through 2050. Methods: Using the Global Burden of Disease (GBD) database 2021, we investigated the characteristics of PC burden in China, including temporal trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs). Age-period-cohort models, frontier analysis, decomposition analysis and prediction models were used for data analyze. Results: In 2021, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR) reached 9.34, 59.86, 4.89, and 76.97 (per 100 000), respectively. The ASIR and ASPR in 2021 increased by 87.17 % and 209.03 %, respectively, compared with 1990, while the ASMR and ASDR remained stable. The relative risk (RR) of PC increases with age, with the highest risk of incidence at 85-89 years. By 2050, the projected age-standardized rate for incidence and mortality are expected to reach 20.85 and 5.11 per 100,000, respectively. Decomposition analysis indicated that population aging and epidemiological shifts primarily drove the increasing PC burden in China. Conclusions: We found that the burden of PC in China is rapidly rising, with an increasing proportion of young patients, posing a serious threat to men's health in China currently and also in 2050. Our findings suggest strengthening early screening programs and prevention strategies for high-risk groups of PC in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.